

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	6228488
<b>Application Number:</b>	10588323
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	2783
<b>Title of Invention:</b>	Methods of treating skin disorders
<b>First Named Inventor/Applicant Name:</b>	Daniel Magilavy
<b>Customer Number:</b>	23460
<b>Filer:</b>	Christine M. Cochran/Jeannie Rapstad
<b>Filer Authorized By:</b>	Christine M. Cochran
<b>Attorney Docket Number:</b>	253780
<b>Receipt Date:</b>	08-OCT-2009
<b>Filing Date:</b>	16-FEB-2007
<b>Time Stamp:</b>	15:45:59
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$1920
RAM confirmation Number	2049
Deposit Account	121216
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

**File Listing:**

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	253780_RCE-Transmittal.pdf	86699 36e47138700a608662f5b14c420c37b7698197	no	2
<b>Warnings:</b>					
This is not a USPTO supplied RCE SB30 form.					
<b>Information:</b>					
2	Amendment Submitted/Entered with Filing of CPA/RCE	253780_SubAccompanyRCE.pdf	379251 86ac2522bca1c11a5d974dbd581d6372819b4b7a7	no	10
<b>Warnings:</b>					
<b>Information:</b>					
3	Transmittal Letter	253780_SupplIDS.pdf	224236 f5535e5660254423c3eca1218c660136c3412c9	no	4
<b>Warnings:</b>					
<b>Information:</b>					
4	Information Disclosure Statement (IDS) Filed (5B/08)	253780_Supp1449.pdf	80528 07ac6d85821c0d2cwe81c254786a8043245c05	no	1
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
5	NPL Documents	C627_BIOGEN-IDEA-2005.pdf	55540 7ad377623b78c34b1b14fc0954607ae1ff1335	no	1
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	C628_CIPO_OfficeAction_4-30-09.pdf	138106 2e5fb34b0b74c4d1d84b41c1b1e0cdd060316	no	3
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	C629_CIPO_OfficeAction_5-01-09.pdf	164650 ebcd641c385a787d18c3d9c97245d464213f84e	no	3
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	C630_CIPO_OfficeAction_8-13-09.pdf	159520 772a1221262a69826c9862a2888b6d7d4379e4	no	3

<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	C631_EPO_OfficeAction_1-29-08.pdf	181782 2f1a2713779100b4c59d1c1d78a970b25d	no	4
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	C632_EPO-OfficeAction_7-24-08.pdf	97069 6b2774e48f71bb1dcd244c744ef135577b33	no	3
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	C633_EPO_OfficeAction_5-08-09.pdf	226115 663af9e3c3d1c5528d6f7347b7028ba0b990b	no	4
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	C634_Gordon_J-Dermatology2003.pdf	1598703 c3ff1172bf06e547d21e65ced470d63bd5d8e1	no	6
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	C635_Magilavy_1998.pdf	749239 919d55f8d43010d9d9d2532a56dc0f5c144bdcdd	no	6
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	C636_Miller_JExpMed_1993.pdf	1179671 0583d3246c35142e3afed664cee112ed9a10ba005	no	12
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	C637_SubmissionRCE_9-15-09.pdf	776373 3605dc6d41c0eef71cd4226e7150d769d3d156b	no	17
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	C638_USPTO-OfficeAction_12-24-08.pdf	687830 1274b99ec8b1811d4d7b5d9854f08937157bb13	no	12
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	C639_USPTO-OfficeAction_2-04-09.pdf	4459413 7163718c0061c394c8ba9e65228d4d995f408b	no	49

**Warnings:****Information:**

18	Fee Worksheet (PTO-875)	fee-info.pdf	31798	no	2
			462125ff4de0839191312-d1ff8ba9f1673185		

**Warnings:****Information:**

Total Files Size (in bytes):	11276523
------------------------------	----------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.